PT3442578T - Métodos para determinar e alcançar doses terapêuticas eficazes de agentes anti-cd47 no tratamento do cancro - Google Patents
Métodos para determinar e alcançar doses terapêuticas eficazes de agentes anti-cd47 no tratamento do cancroInfo
- Publication number
- PT3442578T PT3442578T PT177832540T PT17783254T PT3442578T PT 3442578 T PT3442578 T PT 3442578T PT 177832540 T PT177832540 T PT 177832540T PT 17783254 T PT17783254 T PT 17783254T PT 3442578 T PT3442578 T PT 3442578T
- Authority
- PT
- Portugal
- Prior art keywords
- cancer
- agents
- determining
- treatment
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323330P | 2016-04-15 | 2016-04-15 | |
| US201662427679P | 2016-11-29 | 2016-11-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3442578T true PT3442578T (pt) | 2022-05-19 |
Family
ID=60042716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT177832540T PT3442578T (pt) | 2016-04-15 | 2017-04-14 | Métodos para determinar e alcançar doses terapêuticas eficazes de agentes anti-cd47 no tratamento do cancro |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11472878B2 (enExample) |
| EP (3) | EP3442578B1 (enExample) |
| JP (3) | JP7532009B2 (enExample) |
| KR (3) | KR20240016445A (enExample) |
| CN (3) | CN117695387A (enExample) |
| AU (2) | AU2017250809B2 (enExample) |
| CA (1) | CA3019676A1 (enExample) |
| ES (1) | ES2909835T3 (enExample) |
| PL (1) | PL3442578T3 (enExample) |
| PT (1) | PT3442578T (enExample) |
| SI (1) | SI3442578T1 (enExample) |
| WO (1) | WO2017181033A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018081898A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| PL4177270T3 (pl) | 2017-10-18 | 2024-11-18 | Forty Seven, Inc. | Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47 |
| EP3752190B1 (en) * | 2018-02-12 | 2022-07-06 | Forty Seven, Inc. | Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies |
| GB201804860D0 (en) | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
| WO2020009725A1 (en) * | 2018-07-05 | 2020-01-09 | Trican Biotechnology Co., Ltd | Human anti-cd47 antibodies and uses thereof |
| SG11202102851XA (en) | 2018-09-27 | 2021-04-29 | Celgene Corp | SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF |
| UA128431C2 (uk) | 2018-11-26 | 2024-07-10 | Форті Севен, Інк. | ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit |
| KR20210094609A (ko) | 2018-11-28 | 2021-07-29 | 포티 세븐, 인코포레이티드 | 절제 레짐에 대해 저항성인 유전적으로 변형된 hspc |
| AU2020350205A1 (en) | 2019-09-18 | 2022-05-12 | Lamkap Bio Alpha AG | Bispecific antibodies against CEACAM5 and CD3 |
| JP7369297B2 (ja) | 2019-12-17 | 2023-10-25 | ファイザー・インク | Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用 |
| US20230081265A1 (en) * | 2020-04-06 | 2023-03-16 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody formulation |
| IL301972A (en) * | 2020-10-09 | 2023-06-01 | Sana Biotechnology Inc | Methods for activating safe killing mechanisms using the CD47–SIRPα blocking factor |
| WO2022140659A2 (en) | 2020-12-23 | 2022-06-30 | D-10 Therapeutics, Inc. | Anti-cd47 antibodies and uses thereof |
| JP2024503822A (ja) * | 2021-01-05 | 2024-01-29 | ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン | Ｇｐｃ３及びｃｄ４７を標的とする二重特異性抗体 |
| WO2023002415A2 (en) * | 2021-07-20 | 2023-01-26 | Magenta Therapeutics, Inc. | Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment |
| EP4516807A1 (en) | 2023-08-28 | 2025-03-05 | Consorcio Centro de Investigación Biomédica en Red | Compositions for use in a method of providing improved hematopoietic stem cell engraftment |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008304111B2 (en) * | 2007-09-27 | 2014-04-24 | Amgen Inc. | Pharmaceutical formulations |
| PT3056515T (pt) | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Métodos para manipulação da fagocitose mediada por cd47 |
| EP2249801A2 (en) * | 2008-02-07 | 2010-11-17 | Amgen Inc. | Stabilized protein compositions |
| AU2011252851B2 (en) | 2010-05-14 | 2016-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to CD47 |
| EP3766511A1 (en) | 2012-01-17 | 2021-01-20 | The Board of Trustees of the Leland Stanford Junior University | High affinity sirp-alpha reagents |
| ME03512B (me) | 2012-02-06 | 2020-04-20 | Inhibrx Inc | Cd47 antitijela i postupci za njihovu upotrebu |
| SG10201706383XA (en) | 2013-02-06 | 2017-09-28 | Inhibrx Lp | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
| CN105189556A (zh) * | 2013-03-15 | 2015-12-23 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
| JP6615745B2 (ja) * | 2013-03-27 | 2019-12-04 | ジェネンテック， インコーポレイテッド | ベータ７インテグリンアンタゴニストによる胃腸炎症障害の治療を評価するためのバイオマーカーの使用 |
| WO2014179132A1 (en) * | 2013-04-29 | 2014-11-06 | The Board Of Trustees Of The Leland Stanford Junior University | Use of anti-cd47 agents to enhance immunization |
| EP3052119B1 (en) | 2013-10-01 | 2018-08-22 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Methods of modulating erythropoiesis with arginine vasopressin receptor 1b molecules |
| US11046763B2 (en) | 2014-01-08 | 2021-06-29 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted therapy for small cell lung cancer |
| EP3151855B1 (en) * | 2014-06-08 | 2021-11-24 | REMD Biotherapeutics, Inc. | Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies |
| US20170233485A1 (en) | 2014-08-18 | 2017-08-17 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| AU2015329696A1 (en) * | 2014-10-10 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods to eliminate cancer stem cells by targeting CD47 |
| US20230081265A1 (en) * | 2020-04-06 | 2023-03-16 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody formulation |
-
2017
- 2017-04-14 KR KR1020247002294A patent/KR20240016445A/ko active Pending
- 2017-04-14 PL PL17783254T patent/PL3442578T3/pl unknown
- 2017-04-14 SI SI201731120T patent/SI3442578T1/sl unknown
- 2017-04-14 KR KR1020187032126A patent/KR102505253B1/ko active Active
- 2017-04-14 EP EP17783254.0A patent/EP3442578B1/en active Active
- 2017-04-14 CN CN202311544173.5A patent/CN117695387A/zh active Pending
- 2017-04-14 AU AU2017250809A patent/AU2017250809B2/en active Active
- 2017-04-14 WO PCT/US2017/027662 patent/WO2017181033A1/en not_active Ceased
- 2017-04-14 ES ES17783254T patent/ES2909835T3/es active Active
- 2017-04-14 US US16/089,115 patent/US11472878B2/en active Active
- 2017-04-14 EP EP24159469.6A patent/EP4349412A3/en active Pending
- 2017-04-14 PT PT177832540T patent/PT3442578T/pt unknown
- 2017-04-14 CN CN201780029157.9A patent/CN109152837A/zh active Pending
- 2017-04-14 KR KR1020237006777A patent/KR20230035435A/ko not_active Ceased
- 2017-04-14 CA CA3019676A patent/CA3019676A1/en active Pending
- 2017-04-14 JP JP2018553360A patent/JP7532009B2/ja active Active
- 2017-04-14 CN CN202210926503.6A patent/CN115350276A/zh active Pending
- 2017-04-14 EP EP22155479.3A patent/EP4074339A1/en active Pending
-
2022
- 2022-09-02 JP JP2022140214A patent/JP7442591B2/ja active Active
- 2022-09-08 US US17/930,621 patent/US11718670B2/en active Active
-
2023
- 2023-06-15 US US18/210,483 patent/US20230406923A1/en active Pending
-
2024
- 2024-02-20 JP JP2024023723A patent/JP2024059764A/ja active Pending
- 2024-05-22 AU AU2024203396A patent/AU2024203396A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4349412A3 (en) | 2024-06-12 |
| WO2017181033A1 (en) | 2017-10-19 |
| SI3442578T1 (sl) | 2022-05-31 |
| KR102505253B1 (ko) | 2023-03-02 |
| EP3442578A1 (en) | 2019-02-20 |
| US20190106491A1 (en) | 2019-04-11 |
| JP2019515899A (ja) | 2019-06-13 |
| KR20180134367A (ko) | 2018-12-18 |
| CA3019676A1 (en) | 2017-10-19 |
| CN117695387A (zh) | 2024-03-15 |
| AU2017250809A1 (en) | 2018-10-25 |
| JP2024059764A (ja) | 2024-05-01 |
| US11472878B2 (en) | 2022-10-18 |
| KR20240016445A (ko) | 2024-02-06 |
| US20230068235A1 (en) | 2023-03-02 |
| PL3442578T3 (pl) | 2022-06-20 |
| CN109152837A (zh) | 2019-01-04 |
| JP2022172278A (ja) | 2022-11-15 |
| EP4074339A1 (en) | 2022-10-19 |
| US20230406923A1 (en) | 2023-12-21 |
| ES2909835T3 (es) | 2022-05-10 |
| JP7532009B2 (ja) | 2024-08-13 |
| AU2024203396A1 (en) | 2024-06-06 |
| EP3442578A4 (en) | 2019-04-10 |
| CN115350276A (zh) | 2022-11-18 |
| US11718670B2 (en) | 2023-08-08 |
| KR20230035435A (ko) | 2023-03-13 |
| EP3442578B1 (en) | 2022-02-09 |
| AU2017250809B2 (en) | 2024-02-29 |
| EP4349412A2 (en) | 2024-04-10 |
| JP7442591B2 (ja) | 2024-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3442578T3 (pl) | Sposoby określania i osiągania terapeutycznie skutecznych dawek środków anty-cd47 w leczeniu nowotworów | |
| ZA201904695B (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| IL258955A (en) | Compositions and methods for treatment of cancer | |
| IL257147B (en) | Combined treatment using liposomal irinotecan and a parp inhibitor for cancer treatment | |
| ZA201701491B (en) | Methods and therapeutic combinations for treating tumors | |
| IL254842B (en) | Therapeutic preparations and methods for use in cancer treatment | |
| IL266198A (en) | Liposomal formulation for use in cancer treatment | |
| PL3490560T3 (pl) | Niraparyb do stosowania w sposobie leczenia nowotworu prostaty | |
| IL266182A (en) | Farensyltransferase inhibitors for use in cancer treatment methods | |
| IL254228B (en) | Cell therapeutic agent for cancer treatment and combination therapy with same | |
| IL261648A (en) | Cinnolin-4-amine compounds and their use in treating cancer | |
| IL259358A (en) | Bis-pyridazine compounds and their use in treating cancer | |
| HUE063428T2 (hu) | PI3K P-DELTA 110 gátlószerei rák kezelésében vírusok bejuttatására történõ alkalmazásra | |
| SG10202001388YA (en) | Use of ureidomustine (bo-1055) in cancer treatment | |
| HUE045185T2 (hu) | Új terápiás vegyület és terápiában történõ alkalmazása | |
| IL256763A (en) | Compositions and methods for treating cancer | |
| GB201600637D0 (en) | Therapeutic treatment methods and apparatus for use therein | |
| GB201612793D0 (en) | Therapeutic use of quesnoin in colorectal cancer treatment | |
| GB201612794D0 (en) | Therapeutic use of diethanololeamide in prostate cancer treatment | |
| AU2016905362A0 (en) | Compounds and use thereof in methods of treatment | |
| GB201510764D0 (en) | bis-Pyridazine compounds and their use in treating cancer | |
| GB201418640D0 (en) | Agents and methods for treatment of cancer | |
| GB201403086D0 (en) | Selection of virus and agent useful in the treatment of cancer |